Clinical Trials
Multi-Cancer Trials
Some clinical trials are not limited to a single cancer type. These are called multi-cancer trials, and they may include patients with different tumour types that share specific features—such as genetic mutations or biomarkers.
Learn More Cancer
For general information on cancer—including risk factors, symptoms, diagnosis, and treatment—visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| AWT020-001 | Other Cancers | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer | Immunotherapy | Anti-PD1 IL-2 BiTE. | Open - Recruiting | Anwita Biosciences | NCT06092580 | Enquire Now |
| PTT-4256-01 | Other Cancers | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| DM002001 | Other Cancers | A Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Doma Biopharmaceutical（Suzhou）Co., Ltd. | NCT06751329 | Enquire Now |
| ADCE-B05-001 | Other Cancers | A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients with Advanced Solid Tumors | Immunotherapy | ADC anti-GPC1 IgG1 with a Topo-I inhibitor and P1021 | Open - Recruiting | Adcendo ApS | NCT07362888 | Enquire Now |
| SP-03-B101 | Other Cancers | A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Combination with Exemestane in Patients with Advanced mTOR-sensitive solid tumors (HR+/HER2- Br Ca, RCC, NETs, TSC, HCC) | Targeted | Intravenous Everolimus. HR+ HER2- breast, HCC, RCC, NETs TSC- associated tumours | Open - Recruiting | Sapu Bioscience | ACTRN12625001083482 | Enquire Now |
| GIANTS-1 | Cancer Survivors | A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors (GIANTS-1) | Immunotherapy | Bispecific immunocytokine composed of CD80 fused with a mutated interleukin (IL)-2. In combo with probiotic. | Open - Recruiting | GI Innovation, Inc. | NCT07363057 | Enquire Now |
| HDM2017-101 | Other Cancers | A Phase 1 Study of HDM2017 in Advanced Solid Tumors | Targeted | ADC targeting CDH17 conjugated to CPT-derivative payloads | Open - Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07274085 | Enquire Now |